CStone announces 1st dosed patient in China for advanced GIST trial
Category: #health  By Mateen Dalal  Date: 2019-08-27
  • share
  • Twitter
  • Facebook
  • LinkedIn

CStone announces 1st dosed patient in China for advanced GIST trial

Leading biopharmaceutical expert CStone Pharmaceuticals has reportedly announced the first person in China to be dosed for the Phase I/II bridging trial of Avapritinib, discovered by Blueprint Medicines, a partner of CStone.

This China-based standalone study is a registrational bridging trial including studies of dose-escalation in Phase I and dose-expansion in Phase II, aimed at assessing the efficiency, safety and pharmacokinetics of Avapritinib in patients suffering from metastatic or uresectable GIST (gastrointestinal stromal tumors).

Patients involved in this study are mostly those suffering from PDGFRA D842V- driven GIST, second or third-line GIST or later GIST.

For the uninitiated, GIST is a type of sarcoma, usually found in the wall of the stomach or in the small intestine. GIST is usually detected among patients between 50-80 years of age. Nearly 90% of GIST cases are related to cell growth dysregulation caused by PDGFRA and KIT tyrosine kinases mutation. There are presently no effectual treatments for patients suffering from PDGFRA D842V- driven GIST.

Avapritinib is an orally administered highly selective and potent KIT and PDGFRA inhibitor. Preclinical studies from previously published studies have revealed that Avapritinib shows strong activity against GIST-related PDGFRA and KIT mutant kinases.

Chairman & CEO of CStone, Dr. Frank Jiang has reportedly commented that patients suffering from PDGFRA D842V kinases mutations still lack efficient care even as GIST incident rates continue to rise and expressed CStone’s commitment towards the evolution of ground-breaking therapies designed to fulfill urgent medical needs. He further stated CStone’s wish to follow in the footsteps of their partner Blueprint Medicines, who have submitted an NDA for Avapritinib in the US and an application for marketing authorization in the EU, by giving patients in Greater China access to this innovative precision therapy at the earliest.

CStone’s Chief Medical Officer, Dr. Jason Yang spoke about the data presented from their global Phase I Navigator study of Avapritinib, presented at the ASCO 2019 annual meeting, which showed an 86% objective response rate and promising tolerability in GIST patients with PDGFRA Exon 18 mutations.

Source Credit: http://www.cstonepharma.com/en/html/news/2196.html

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

Mateen has completed his Bachelor’s degree in electronics and telecommunication engineering, post which he lent his proficiency to the industry, working as a quality and test engineer. Drawn intricately toward the field of content creation however, Mateen soon switc...

Read More

More News By Mateen Dalal

Google’s business intelligence platform Looker collabs with Tableau
Google’s business intelligence platform Looker collabs with Tableau
By Mateen Dalal

Google Cloud Platform has recently revealed that its business intelligence platform, Looker has been integrated with Tableau, empowering users of both the platforms to benefit from the different features offered by each. For starters, Google Cloud a...

HR tech firm Personio ropes in $270 million in latest financing round
HR tech firm Personio ropes in $270 million in latest financing round
By Mateen Dalal

Personio, a HR software provider targeting small and medium sized businesses, has attained a $270 million investment in the wake of high demand for its services. With the latest Series E round of funding, Personio's valuation roses to $6.3 billi...

New Zealand prepares to deal with potential surge in COVID-19 cases
New Zealand prepares to deal with potential surge in COVID-19 cases
By Mateen Dalal

New Zealand is preparing for an increase in Covid-19 cases after registering 94 new infections over the weekend, with pandemic modelers predicting that if the government continues on its present path, new cases would rapidly exceed 100 per day. Epid...